Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06531863 · ClinicalTrials.gov registry record · Early Phase 1
Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance
A Early Phase 1 study of Mood Disturbance, sponsored by Auburn University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06531863: Recruiting Early Phase 1 study of Mood Disturbance, sponsored by Auburn University.
NCT06531863 is a Early Phase 1 study of Mood Disturbance that is actively recruiting participants, run by Auburn University. The registered enrollment target is 64 participants, above the 45-participant average among 3 other Mood Disturbance trials with a reported enrollment target (42% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06531863, a Early Phase 1 study of Mood Disturbance, is actively recruiting participants, sponsored by Auburn University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)
Primary Outcome
The DASS-21 (Depression Anxiety and Stress Scale) Total ranges from 0 to 63, with lower numbers indicating less distress
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Curcumin
- DIETARY_SUPPLEMENT Epigallocatechin Gallate
Study Locations (1)
Alabama
- Auburn University School of Kinesiology - Auburn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2025-08-01 |
| Phase | Early Phase 1 |
What NCT06531863 shows while recruiting
NCT06531863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, above the 45-participant average among 3 other Mood Disturbance trials with a reported enrollment target (42% higher).
The record links to 1 condition, with Mood Disturbance appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06531863 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT06531863 about?
NCT06531863 is a clinical study titled "Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance". The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance sy...
What is the current status of trial NCT06531863?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 64 participants. The study started on 2024-09-30. Estimated completion is 2025-08-01.
What conditions does trial NCT06531863 study?
This clinical trial studies the following conditions: Mood Disturbance.
What interventions are being tested in trial NCT06531863?
The interventions under investigation include: Placebo (OTHER), Curcumin (DIETARY_SUPPLEMENT), Epigallocatechin Gallate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06531863?
This trial is sponsored by Auburn University, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06531863 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mood Disturbance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI